Clinical Trials
0
0 active
Approvals
24
Total approvals
Agencies
3
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- Thermo Fisher Scientific has opened a new Cryo-Electron Microscopy Drug Discovery Center in South San Francisco to provide pharmaceutical and biotechnology companies with advanced cryo-EM technologies for accelerated drug development. - Structure-guided drugs developed using cryo-EM technology demonstrate more than twice the clinical success rate in half the preclinical time and at half the cost compared to industry standards. - The new center builds on the success of the UK Pharmaceutical Cryo-EM Consortium established in 2016, extending this collaborative approach to the North American market with founding customer members. - Located in Oyster Point, the center combines state-of-the-art cryo-EM instrumentation with collaborative scientific environments to expedite the path from drug discovery to development.
- Thermo Fisher Scientific introduces Accelerator Drug Development, an integrated CDMO and CRO solution designed to streamline pharmaceutical development from early research to commercialization. - The platform addresses critical industry challenges including escalating R&D costs estimated at $1.3-2.8 billion per approved drug and inefficiencies caused by fragmented vendor relationships. - The integrated approach provides single-vendor accountability across clinical research, manufacturing, and supply chain operations, targeting both small biotech companies and large pharmaceutical organizations. - Clinical trials account for 70% of total R&D expenditures, making coordination improvements in trial design, execution, and supply chain management key cost reduction opportunities.
